AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37505117 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of pack-years
Number of subjects: 576
Study 37505258 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative acute kidney injury (PO-AKI)
Number of subjects: 10568
Study 37505258 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 10568
Study 37505258 — intervention group
Group type: COMPARATOR
Intervention: ICU mortality
Number of subjects: 10568
Study 37505258 — intervention group
Group type: COMPARATOR
Intervention: Hospital mortality
Number of subjects: 10568
Study 37505258 — intervention group
Group type: COMPARATOR
Intervention: ICU length of stay
Number of subjects: 10568
Study 37505258 — intervention group
Group type: COMPARATOR
Intervention: Hospital length of stay
Number of subjects: 10568
Study 37505337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 3680
Study 37505379 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy combined with LITT
Number of subjects: 15
Study 37505379 — intervention group
Group type: COMPARATOR
Intervention: Biopsy alone
Number of subjects: 15
Study 37505393 — intervention group
Group type: EXPERIMENTAL
Intervention: Exit interviews with MLP, CLP, and LPP patients
Number of subjects: 26
Study 37505393 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent qualitative interviews with CLP patients
Number of subjects: 26
Study 37505401 — intervention group
Group type: EXPERIMENTAL
Intervention: Former preterm birth and/or ELBW infants
Number of subjects: 304
Study 37505401 — intervention group
Group type: COMPARATOR
Intervention: Full-term infants (control group)
Number of subjects: 304
Study 37505420 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-volume tubes
Number of subjects: 369
Study 37505420 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume tubes
Number of subjects: 369
Study 37505794 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) in frontline regimens for high-risk disease
Number of subjects: 0
Study 37505794 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) and checkpoint inhibitor therapy
Number of subjects: 0
Study 37505794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bv/nivolumab
Number of subjects: 0
Study 37506059 — intervention group
Group type: EXPERIMENTAL
Intervention: Music with tapping
Number of subjects: 59
Study 37506059 — intervention group
Group type: COMPARATOR
Intervention: Silence without tapping
Number of subjects: 59
Study 37506059 — intervention group
Group type: COMPARATOR
Intervention: Simply tapping without music
Number of subjects: 59
Study 37506163 — intervention group
Group type: EXPERIMENTAL
Intervention: INTER-ACT postpartum lifestyle intervention (4 face-to-face coaching sessions, supported by an e-health app)
Number of subjects: 1047
Study 37506163 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 1047
Study 37506264 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 234
Study 37506264 — intervention group
Group type: COMPARATOR
Intervention: Investigator-assigned standard therapy (IAT)
Number of subjects: 234
Study 37506329 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO300
Number of subjects: 258
Study 37506329 — intervention group
Group type: COMPARATOR
Intervention: ENCO300 (parts 1 and 2 combined)
Number of subjects: 258
Study 37506329 — intervention group
Group type: COMPARATOR
Intervention: ENCO300 (part 2)
Number of subjects: 258
Study 37506339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone (RD)
Number of subjects: 332
Study 37506339 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone plus ixazomib (IRD)
Number of subjects: 332
Study 37506339 — intervention group
Group type: EXPERIMENTAL
Intervention: RD maintenance therapy
Number of subjects: 332
Study 37506346 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus Obinutuzumab (ZO)
Number of subjects: 217
Study 37506346 — intervention group
Group type: COMPARATOR
Intervention: Obinutuzumab (O)
Number of subjects: 217
Study 37506513 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS complete deletions/large rearrangements (n=7)
Number of subjects: 88
Study 37506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete deletions/large rearrangements (n=4)
Number of subjects: 88
Study 37506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Splice site variants (n=4)
Number of subjects: 88
Study 37506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclassifiable variants (n=3)
Number of subjects: 88
Study 37506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Splice site variants (n=5)
Number of subjects: 88
Study 37506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (n=88)
Number of subjects: 88
Study 37506557 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell vaccine combined with romidepsin (RMD)
Number of subjects: 11
Study 37506557 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD33 antibody
Number of subjects: 11
Study 37506599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks
Number of subjects: 130
Study 37506599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 37506599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks with ideal compliance
Number of subjects: 130
Study 37506747 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster heart rate
Number of subjects: 0
Study 37506846 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab
Number of subjects: 2117
Study 37506846 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 2117
Study 37506846 — intervention group
Group type: EXPERIMENTAL
Intervention: commercially insured patients
Number of subjects: 2117
Study 37506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 1498
Study 37506972 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1498
Study 37506972 — intervention group
Group type: EXPERIMENTAL
Intervention: TVF-first event
Number of subjects: 1498
Study 37506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-TVF-first event
Number of subjects: 1498
Study 37506972 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 1498
Study 37506974 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (BF)
Number of subjects: 115
Study 37506974 — intervention group
Group type: COMPARATOR
Intervention: Exclusive formula feeding (FF)
Number of subjects: 115
Study 37506974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus (in BF group)
Number of subjects: 115
Study 37507196 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Convolutional Neural Network (DCNN) model using ResNet-50 architecture
Number of subjects: 6784
Study 37507196 — intervention group
Group type: COMPARATOR
Intervention: Deep Convolutional Neural Network (DCNN) model
Number of subjects: 6784
Study 37507274 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of BNT162b2 mRNA COVID-19 vaccine
Number of subjects: 1758
Study 37507274 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated or vaccinated with other vaccines)
Number of subjects: 1758
Study 37507392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ARVAC CG
Number of subjects: 0
Study 37507392 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ARVAC CG
Number of subjects: 0
Study 37507392 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (control group)
Number of subjects: 0
Study 37507425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily for a median of 14 days)
Number of subjects: 184
Study 37507425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 184
Study 37507427 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exacerbation of COPD requiring hospitalization
Number of subjects: 121
Study 37507427 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity during hospitalization and recovery
Number of subjects: 121
Study 37507427 — intervention group
Group type: COMPARATOR
Intervention: Control group with stable COPD
Number of subjects: 121
Study 37507543 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, or both in combination with chemotherapy
Number of subjects: 41
Study 37507543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 41
Study 37507580 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal Vessel Analysis (RVA) in PCS patients
Number of subjects: 41
Study 37507657 — intervention group
Group type: EXPERIMENTAL
Intervention: Galunisertib 150 mg twice daily (14 days on/14 days off) plus nivolumab 3 mg/kg (IV every 2 weeks)
Number of subjects: 25
Study 37507657 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 37507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-led online group seated strength exercises using resistance bands, once weekly for 6 months
Number of subjects: 30
Study 37507692 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 39
Study 37507692 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet combined with other interventions (exercise, smoking cessation)
Number of subjects: 39
Study 37507692 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological dietary interventions
Number of subjects: 39
Study 37507720 — intervention group
Group type: COMPARATOR
Intervention: Usual Implementation (UI)
Number of subjects: 1296
Study 37507720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Supervision (ES)
Number of subjects: 1296
Study 37507720 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Engaged Learning Collaborative (CELC)
Number of subjects: 1296
Study 37507720 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (UI, ES, CELC)
Number of subjects: 1296
Study 37507720 — intervention group
Group type: EXPERIMENTAL
Intervention: CHS staff and non-CHS staff
Number of subjects: 1296
Study 37507763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-replete beetroot juice (400 mg nitrate/day)
Number of subjects: 60
Study 37507763 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-deplete beetroot juice (placebo)
Number of subjects: 60
Study 37507772 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home decluttering led by a social services team for 10 weeks
Number of subjects: 90
Study 37507772 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study 37507802 — intervention group
Group type: EXPERIMENTAL
Intervention: XL102
Number of subjects: 54
Study 37507802 — intervention group
Group type: EXPERIMENTAL
Intervention: XL102 with Venetoclax
Number of subjects: 54
Study 37508596 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led memory-reframing intervention
Number of subjects: 74
Study 37508596 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 37508992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) coupled with language therapy
Number of subjects: 0
Study 37508992 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37509027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise program
Number of subjects: 0
Study 37509027 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable near-infrared spectroscopy (NIRS) measures
Number of subjects: 0
Study 37509349 — intervention group
Group type: EXPERIMENTAL
Intervention: Canady Helios Cold Plasma (CHCP) treatment during surgical resection
Number of subjects: 20
Study 37509349 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical resection without CHCP)
Number of subjects: 20
Study 37509587 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA alone
Number of subjects: 0
Study 37509587 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA/GAD65-alum treatment
Number of subjects: 0
Study 37509587 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37510718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (n=74)
Number of subjects: 277
Study 37510718 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (n=203)
Number of subjects: 277
Study 37510828 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of ECG repolarization markers
Number of subjects: 215
Study 37510953 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-strain probiotic formulations
Number of subjects: 0
Study 37510953 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37510965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 31
Study 37510965 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study 37511184 — intervention group
Group type: EXPERIMENTAL
Intervention: whey-based extensively hydrolyzed formula (EHF) supplemented with 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT)
Number of subjects: 194
Study 37511184 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 194
Study 37511562 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapy (Yescarta™)
Number of subjects: 0
Study 37511562 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 37511870 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 0
Study 37511870 — intervention group
Group type: EXPERIMENTAL
Intervention: ISCHEMIA study
Number of subjects: 0
Study 37511870 — intervention group
Group type: EXPERIMENTAL
Intervention: ISCHEMIA sub-analyses
Number of subjects: 0
Study 37511870 — intervention group
Group type: EXPERIMENTAL
Intervention: ISCHEMIA-CKD substudy
Number of subjects: 0
Study 37512932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic OMNi-BiOTiC
Number of subjects: 0
Study 37513930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 201
Study 37513930 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 201
Study 37515050 — intervention group
Group type: EXPERIMENTAL
Intervention: TURKOVAC
Number of subjects: 190
Study 37515050 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 190
Study 37515050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TURKOVAC and CoronaVac
Number of subjects: 190
Study 37515050 — intervention group
Group type: EXPERIMENTAL
Intervention: Single booster dose
Number of subjects: 190
Study 37515194 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of probenecid every 12 h for five days
Number of subjects: 75
Study 37515194 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of probenecid every 12 h for five days
Number of subjects: 75
Study 37515194 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 h for five days
Number of subjects: 75
Study 37515446 — intervention group
Group type: EXPERIMENTAL
Intervention: RF toothbrush
Number of subjects: 58
Study 37515446 — intervention group
Group type: COMPARATOR
Intervention: Control (sham toothbrush)
Number of subjects: 58
Study 37515459 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) therapy within 6 hours of symptom onset
Number of subjects: 456
Study 37515459 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 456
Study 37515459 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) therapy
Number of subjects: 456
Study 37515636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular function evaluation by video head impulse testing
Number of subjects: 114
Study 37515636 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS 31 questionnaire for autonomic neuropathy
Number of subjects: 114
Study 37515943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C, selenium, zinc, vitamin E, β-carotene) for 3 to 6 months
Number of subjects: 41
Study 37515943 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 to 6 months
Number of subjects: 41
Study 37516125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg twice a day
Number of subjects: 778
Study 37516125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once a day
Number of subjects: 778
Study 37516125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study 37516163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I (Cognitive Behavioral Therapy for Insomnia)
Number of subjects: 2300
Study 37516163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-D (Cognitive Behavioral Therapy for Depression)
Number of subjects: 2300
Study 37516163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I + D (sequential intervention)
Number of subjects: 2300
Study 37516163 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-D + I (sequential intervention)
Number of subjects: 2300
Study 37516163 — intervention group
Group type: COMPARATOR
Intervention: Mood monitoring (control condition)
Number of subjects: 2300
Study 37516163 — intervention group
Group type: EXPERIMENTAL
Intervention: IIR predicted optimal intervention
Number of subjects: 2300
Study 37516163 — intervention group
Group type: EXPERIMENTAL
Intervention: One of the four CBT interventions (randomized)
Number of subjects: 2300
Study 37516165 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone disclosure by a Board-certified genetic counselor
Number of subjects: 4000
Study 37516165 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-guided modality with optional genetic counselor follow-up via telephone
Number of subjects: 4000
Study 37516299 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR calculated using 2 markers (creatinine and cystatin C)
Number of subjects: 106
Study 37516299 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR calculated using 6 different equations based on creatinine; 3 based on creatinine and cystatin C combined; and 2 based on panels of markers including creatinine, cystatin C, β-trace protein (BTP)
Number of subjects: 106
Study 37516398 — intervention group
Group type: EXPERIMENTAL
Intervention: High central sensitization score (>5/10)
Number of subjects: 53
Study 37516398 — intervention group
Group type: COMPARATOR
Intervention: Low central sensitization score (<5/10)
Number of subjects: 53
Study 37516818 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR TKI treatment
Number of subjects: 135
Study 37516818 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SNPs in HLA-DRB5 gene
Number of subjects: 135
Study 37516818 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SNPs in KIR3DL1 and KIR3DL2 genes
Number of subjects: 135
Study 37516830 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 27
Study 37516830 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 27
Study 37516835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (HFSRT) - 6 - 7 × 5 Gy prescribed to the surrounding isodose
Number of subjects: 0
Study 37516835 — intervention group
Group type: COMPARATOR
Intervention: Single fraction stereotactic radiosurgery (SRS) - 1 × 12-20 Gy prescribed to the surrounding isodose
Number of subjects: 0
Study 37516837 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) from a universal donor (n=5)
Number of subjects: 11
Study 37516837 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous FMT (n=6)
Number of subjects: 11
Study 37516837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 11
Study 37516841 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal probiotics
Number of subjects: 202
Study 37516841 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 202
Study 37516867 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPVax vaccine at 0.5 mg subcutaneously combined with atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Number of subjects: 0
Study 37516867 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab (1200 mg IV infusion) and bevacizumab (15 mg/kg IV infusion) every 3 weeks.
Number of subjects: 0
Study 37516873 — intervention group
Group type: EXPERIMENTAL
Intervention: REAtouch virtual device
Number of subjects: 40
Study 37516873 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 37517006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Balance Scale (SBS-T)
Number of subjects: 60
Study 37517037 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular function tests (caloric tests, cVEMP, oVEMP, vHIT, SOT)
Number of subjects: 86
Study 37517037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness handicap inventory (DHI) and visual analogue scale for vertigo (VAS-V)
Number of subjects: 86
Study 37517037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure-tone audiometry (PTA)
Number of subjects: 86
Study 37517110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 171
Study 37517327 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured GFR (mGFR) based on iohexol plasma clearance
Number of subjects: 96
Study 37517413 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib (200 mg orally once per day)
Number of subjects: 195
Study 37517413 — intervention group
Group type: COMPARATOR
Intervention: Danazol (300 mg orally twice per day)
Number of subjects: 195
Study 37517413 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 195
Study 37517422 — intervention group
Group type: EXPERIMENTAL
Intervention: OVX836 180 μg
Number of subjects: 137
Study 37517422 — intervention group
Group type: EXPERIMENTAL
Intervention: OVX836 300 μg
Number of subjects: 137
Study 37517422 — intervention group
Group type: EXPERIMENTAL
Intervention: OVX836 480 μg
Number of subjects: 137
Study 37517422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137